Latest filing published 29 Sept 2010 for Cascadian Therapeutics, Inc., €13k.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Shashi K. Karan: trading record in brief
Shashi K. Karan discloses dealings in Cascadian Therapeutics, Inc. to SEC (Form 4). Between 18 August 2009 and 28 September 2010, the trades on record add up to 4 filings.
No open-market sale appears; the market trades are 4 purchases worth €31k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2010: 1 purchase and no sales on the market.
A typical purchase (the median) is worth €8,533.
On 29 September 2010 came the latest disclosure, an open-market purchase for €13k in Cascadian Therapeutics, Inc. Most trades are made public on the day they happen. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Shashi K. Karan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,100 shares@ US$3.41Common StockSEC:0001457395-10-000001:0Canonical exit: 27 Dec 2010 (T+90)
- 1,200 shares@ US$5.05Common StockSEC:0001457395-09-000005:0Canonical exit: 16 Nov 2009 (T+90)
- 100 shares@ US$5.07Common StockSEC:0001457395-09-000005:1Canonical exit: 16 Nov 2009 (T+90)
- 3,700 shares@ US$5.08Common StockSEC:0001457395-09-000005:2Canonical exit: 16 Nov 2009 (T+90)
4 of 4 declarations